400 related articles for article (PubMed ID: 33780474)
1. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
[TBL] [Abstract][Full Text] [Related]
2. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
[TBL] [Abstract][Full Text] [Related]
3. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
[TBL] [Abstract][Full Text] [Related]
4. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
5. Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis.
Sit YT; Takasaki K; An HH; Xiao Y; Hurtz C; Gearhart PA; Zhang Z; Gadue P; French DL; Chou ST
JCI Insight; 2023 Oct; 8(23):. PubMed ID: 37906251
[TBL] [Abstract][Full Text] [Related]
6. Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model.
Arkoun B; Robert E; Boudia F; Mazzi S; Dufour V; Siret A; Mammasse Y; Aid Z; Vieira M; Imanci A; Aglave M; Cambot M; Petermann R; Souquere S; Rameau P; Catelain C; Diot R; Tachdjian G; Hermine O; Droin N; Debili N; Plo I; Malinge S; Soler E; Raslova H; Mercher T; Vainchenker W
J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35587378
[TBL] [Abstract][Full Text] [Related]
7. Down syndrome-associated haematopoiesis abnormalities created by chromosome transfer and genome editing technologies.
Kazuki Y; Yakura Y; Abe S; Osaki M; Kajitani N; Kazuki K; Takehara S; Honma K; Suemori H; Yamazaki S; Sakuma T; Toki T; Shimizu R; Nakauchi H; Yamamoto T; Oshimura M
Sci Rep; 2014 Aug; 4():6136. PubMed ID: 25159877
[TBL] [Abstract][Full Text] [Related]
8. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
Ge Y; Dombkowski AA; LaFiura KM; Tatman D; Yedidi RS; Stout ML; Buck SA; Massey G; Becton DL; Weinstein HJ; Ravindranath Y; Matherly LH; Taub JW
Blood; 2006 Feb; 107(4):1570-81. PubMed ID: 16249385
[TBL] [Abstract][Full Text] [Related]
9. Prominent megakaryocytic dysplasia after regression of transient abnormal myelopoiesis associated with GATA-1 mutation.
Anoop P; Atra A
J Pediatr Hematol Oncol; 2012 Nov; 34(8):640. PubMed ID: 23007419
[TBL] [Abstract][Full Text] [Related]
10. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
11. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.
Klusmann JH; Li Z; Böhmer K; Maroz A; Koch ML; Emmrich S; Godinho FJ; Orkin SH; Reinhardt D
Genes Dev; 2010 Mar; 24(5):478-90. PubMed ID: 20194440
[TBL] [Abstract][Full Text] [Related]
12. Distinct GATA1 Point Mutations in Monozygotic Twins With Down Syndrome and Transient Abnormal Myelopoiesis From a Triplet Pregnancy: A Case Report and Review of Literature.
Yin L; Lovell MA; Wilson ML; Wei Q; Liang X
Am J Clin Pathol; 2016 Dec; 146(6):753-759. PubMed ID: 28028114
[TBL] [Abstract][Full Text] [Related]
13. The GATA1s isoform is normally down-regulated during terminal haematopoietic differentiation and over-expression leads to failure to repress MYB, CCND2 and SKI during erythroid differentiation of K562 cells.
Halsey C; Docherty M; McNeill M; Gilchrist D; Le Brocq M; Gibson B; Graham G
J Hematol Oncol; 2012 Aug; 5():45. PubMed ID: 22853316
[TBL] [Abstract][Full Text] [Related]
14. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome.
Alford KA; Slender A; Vanes L; Li Z; Fisher EM; Nizetic D; Orkin SH; Roberts I; Tybulewicz VL
Blood; 2010 Apr; 115(14):2928-37. PubMed ID: 20154221
[TBL] [Abstract][Full Text] [Related]
15. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
[TBL] [Abstract][Full Text] [Related]
16. The landscape of somatic mutations in Down syndrome-related myeloid disorders.
Yoshida K; Toki T; Okuno Y; Kanezaki R; Shiraishi Y; Sato-Otsubo A; Sanada M; Park MJ; Terui K; Suzuki H; Kon A; Nagata Y; Sato Y; Wang R; Shiba N; Chiba K; Tanaka H; Hama A; Muramatsu H; Hasegawa D; Nakamura K; Kanegane H; Tsukamoto K; Adachi S; Kawakami K; Kato K; Nishimura R; Izraeli S; Hayashi Y; Miyano S; Kojima S; Ito E; Ogawa S
Nat Genet; 2013 Nov; 45(11):1293-9. PubMed ID: 24056718
[TBL] [Abstract][Full Text] [Related]
17. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
Satgé D
Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
[TBL] [Abstract][Full Text] [Related]
18. Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome.
Toki T; Kanezaki R; Kobayashi E; Kaneko H; Suzuki M; Wang R; Terui K; Kanegane H; Maeda M; Endo M; Mizuochi T; Adachi S; Hayashi Y; Yamamoto M; Shimizu R; Ito E
Blood; 2013 Apr; 121(16):3181-4. PubMed ID: 23440243
[TBL] [Abstract][Full Text] [Related]
19. The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis.
Alejo-Valle O; Weigert K; Bhayadia R; Ng M; Issa H; Beyer C; Emmrich S; Schuschel K; Ihling C; Sinz A; Zimmermann M; Wickenhauser C; Flasinski M; Regenyi E; Labuhn M; Reinhardt D; Yaspo ML; Heckl D; Klusmann JH
Blood; 2022 Feb; 139(5):651-665. PubMed ID: 34570885
[TBL] [Abstract][Full Text] [Related]
20. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.
Kanezaki R; Toki T; Terui K; Xu G; Wang R; Shimada A; Hama A; Kanegane H; Kawakami K; Endo M; Hasegawa D; Kogawa K; Adachi S; Ikeda Y; Iwamoto S; Taga T; Kosaka Y; Kojima S; Hayashi Y; Ito E
Blood; 2010 Nov; 116(22):4631-8. PubMed ID: 20729467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
